Global Implantable Cardiac Rhythm Management Market – Industry Trends and Forecast to 2031

Analyse du marché et de la taille de la gestion du rythme cardiaque implantable

Le marché mondial des dispositifs implantables de gestion du rythme cardiaque connaît une croissance significative, tirée par des facteurs tels que la prévalence croissante des maladies cardiovasculaires, les progrès technologiques et le vieillissement croissant de la population. Selon les données de l'Organisation mondiale de la santé (OMS), les maladies cardiovasculaires, qui représentent plus de 30 % des décès dans le monde, soulignent le besoin crucial de solutions efficaces de gestion du rythme cardiaque. La fibrillation auriculaire (FA) contribue de manière significative à ce marché , affectant environ 33,5 millions de personnes dans le monde. Ces statistiques soulignent l'importance des technologies innovantes et des solutions avancées pour faire face au fardeau croissant des maladies cardiaques. Les fabricants devraient se concentrer sur le développement de dispositifs rentables et peu invasifs pour répondre à cette demande croissante, stimulant ainsi la croissance du marché au cours de la période de prévision.

Français La taille du marché mondial de la gestion du rythme cardiaque implantable était évaluée à 18,62 milliards USD en 2023 et devrait atteindre 26,72 milliards USD d'ici 2031, avec un TCAC de 4,62 % au cours de la période de prévision de 2024 à 2031. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée du rapport et segmentation du marché       

Définition du marché

La gestion du rythme cardiaque implantable (ICRM) fait référence à un ensemble de dispositifs médicaux conçus pour surveiller et gérer l'activité électrique du cœur chez les personnes atteintes de certaines maladies cardiaques. Ces dispositifs sont implantés à l'intérieur du corps et aident à réguler le rythme cardiaque en délivrant des impulsions électriques ou des chocs selon les besoins. Les dispositifs ICRM comprennent les stimulateurs cardiaques, qui aident à maintenir un rythme cardiaque régulier en envoyant des signaux électriques au muscle cardiaque pour réguler son rythme, et les défibrillateurs cardioverteurs implantables (DCI), qui surveillent le rythme cardiaque et délivrent un choc électrique pour rétablir un rythme normal si une arythmie dangereuse est détectée. 

Dynamique du marché de la gestion du rythme cardiaque implantable

Conducteurs

• Prévalence croissante des maladies cardiovasculaires     

Le vieillissement de la population mondiale et la prévalence croissante des modes de vie sédentaires devraient entraîner une augmentation substantielle des maladies cardiovasculaires telles que les arythmies et l’insuffisance cardiaque. Cette tendance fait grimper la demande de dispositifs implantables de gestion du rythme cardiaque (ICRM), car il existe un besoin croissant de solutions efficaces pour gérer ces troubles cardiaques. Par exemple, selon le CDC, la fibrillation auriculaire, le type d’arythmie cardiaque le plus courant, a touché environ 2,7 à 6,1 millions de personnes aux États-Unis en 2017. Cette prévalence croissante des maladies cardiovasculaires est un facteur clé qui alimente l’adoption des dispositifs ICRM à l’échelle mondiale.

• Progrès technologiques dans les dispositifs ICRM

Les progrès constants de la technologie des dispositifs, notamment la miniaturisation, les systèmes de stimulation sans fil et la communication sans fil, transforment fondamentalement les critères d'efficacité et de sécurité des dispositifs ICRM. Ces avancées technologiques améliorent non seulement les résultats pour les patients, mais stimulent également les taux d'adoption de ces implants cardiaques. Les progrès réalisés dans la création de dispositifs plus compacts et plus efficaces augmentent leur accessibilité et leur attractivité pour les patients et les prestataires de soins de santé, propulsant ainsi l'expansion du marché ICRM.

Opportunités

• Développement de dispositifs sans fil

The emergence of leadless pacing systems and other innovative technologies is opening up new pathways for the Implantable Cardiac Rhythm Management (ICRM) market. These cardiac implant devices offer notable advantages, such as a reduced risk of infection and enhanced patient comfort, leading to their increasing adoption among patients and healthcare providers. For instance, in April 2022, Abbott announced that the Aveir single-chamber (VR) leadless pacemaker had obtained approval from the Food and Drug Administration (FDA) for treating patients with slow heart rhythms in the U.S.. This approval marks a significant leap forward in patient care, introducing novel features previously unavailable to patients and their healthcare providers. This evolution of leadless devices is reshaping the landscape of ICRM devices, presenting lucrative opportunities for market players.

• Telemedicine and Remote Monitoring with ICRM Devices

The integration of telemedicine and remote monitoring technologies with ICRM devices is revolutionizing patient care and management. These technologies enable healthcare providers to remotely monitor patients' cardiac activity, leading to early detection of issues and improved patient outcomes. The convenience and efficiency offered by telemedicine and remote monitoring are driving their adoption in the ICRM market, creating new growth prospects for market players.

Restraints/Challenges

• High Cost of ICRM Devices

The excessive cost associated with ICRM devices, including implantation procedures and follow-up care, poses a significant barrier to market growth. This is especially true in developing countries with limited healthcare budgets and infrastructure, where the high cost of these devices can deter patients from opting for them. To overcome this challenge, market players need to focus on developing cost-effective solutions and expanding access to these devices in emerging markets.

• Risks Associated with Implantation

The implantation of ICRM devices comes with inherent risks, such as infection, device malfunction, and lead complications. These risks can deter patients from opting for these devices and impact market growth. To mitigate these risks, healthcare providers need to ensure proper patient selection, implantation techniques, and post-operative care. In addition, ongoing advancements in cardiac implantable devices technology aim to reduce these risks, making ICRM devices safer and more reliable for patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICDs) and the INVICTA defibrillation lead in Japan, enhancing their global product portfolio
• In January 2022, Medtronic plc disclosed that it had obtained approval from Japan's Ministry of Health, Labor and Welfare for both the sale and reimbursement of the Micra AV Transcatheter Pacing System (TPS)

Implantable Cardiac Rhythm Management Market Scope

The market is segmented on the basis of product and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Pacemakers
  • Implantable
  • External
• Defibrillators
  • Implantable Cardioverter Defibrillators (ICD)
    • S-ICD
    • T-ICD
  • External Defibrillator
    • Manual External Defibrillator
    • Automatic External Defibrillator
    • Wearable Cardioverter Defibrillator
• Cardiac Resynchronization Therapy (CRT)
  • CRT-Defibrillator
  • CRT-Pacemakers
• Implantable Loop Recorder

End User

• Hospitals
• Specialty Cardiac Centres
• Ambulatory Surgical Centres
• Others

Implantable Cardiac Rhythm Management Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to advancements in technology, such as miniaturization and the development of leadless or biocompatible materials, which are key drivers propelling market growth in the region. These technological advancements have enabled the creation of smaller, more efficient devices that are more compatible with the human body. In addition, government regulatory approvals play a crucial role in fostering market growth by ensuring the safety and efficacy of these medical devices.

Asia-Pacific is expected to witness significant growth during the forecast period due to the increasing number of elderly individuals and the growing incidence of cardiac disorders. This demographic shift towards an older population has led to a higher demand for cardiac devices, as age is a significant risk factor for cardiovascular diseases. The rising prevalence of cardiac disorders, including heart failure, arrhythmias, and coronary artery disease, is contributing to the market's growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Implantable Cardiac Rhythm Management Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Medtronic (U.S.)
• Abbott (U.S.)
• Stryker (U.S.)
• Asahi Kasei Corporation (Japan)
• Boston Scientific Corporation (U.S.)
• Biotronik (Germany)
• Integer Holdings Corporation (U.S.)
• MicroPort Scientific Corporation (China)
• Koninklijke Philips N.V. (Netherlands)
• ZOLL Medical Corporation (U.S.)
• ABIOMED (U.S.)
• Berlin Heart (Germany)
• Jarvik Heart, Inc. (U.S.)
• NIHON KOHDEN CORPORATION (Japan)
• Defibtech LLC (U.S.)
• Medicalsystem Co., Ltd. (China)
• LivaNova PLC (U.K.)
• Cardiac Science Corporation (U.S.)
• 3M (U.S.)
• Mentice (Sweden)

SKU-43617